Contents
On this page
- Why one patient is the hardest case
- Three permissions, not one
- What the GDPR requires, and what it leaves to your institution
- What journals require, which is the part you control
- What to remove from a transplant case description
- The same case, written two ways
- Fitting it to CARE without losing the clinical message
- What the consent conversation has to cover
- Where this is genuinely unsettled
- Take-home message
- How to apply this to your study
- Common questions
Academy · Research Publication · Case report consent and GDPR
Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection
A single-patient case report is the hardest consent problem in clinical publishing, because the detail that makes the case worth reporting is the same detail that identifies the patient. Three separate permissions are involved and they are not interchangeable: a lawful basis for processing the data, your institution’s ethics position, and the patient’s written consent to publication. Only the third is fully in your hands.
You have a transplant recipient who caught SARS-CoV-2, stayed out of hospital, and kept their graft. It is a case worth publishing: immunosuppression, a novel infection, and a management decision taken without trial evidence. It is also a case in which the transplant date, the centre, the regimen and the timing of infection together point to one identifiable person. This page sets out what has to be removed, what the patient’s consent has to cover, what journals will actually ask for, and where the data-protection answer depends on your country and your institution rather than on anything you can look up.
What you will learn
- Why a single-patient report is harder to de-identify than a cohort study, and why “anonymised” is usually the wrong word for it
- The three distinct permissions a case report needs, who grants each, and which one the journal will check
- Which identifiers to strip from a transplant case description, and which clinical details to keep
- What the ICMJE requires of authors on patient privacy — the part of this you fully control
- How the CARE checklist’s 13 items structure the report once the consent problem is solved
- Where European data-protection guidance is genuinely unsettled, and what to ask your data protection officer
What to unlearn
- “If I remove the name and the hospital number, the case is anonymised.” In a single-patient transplant report it almost never is. Mostert and colleagues, in the European Journal of Human Genetics, set out why the “consent or anonymise” model breaks down on rich clinical data: the narrative itself re-identifies.
- “Consent is my legal basis under the GDPR.” Consent is one of six legal bases, and European guidance has repeatedly concluded it is often not the appropriate one for health research. Your institution, as controller, decides this — not you, and not the patient’s publication consent form.
- “Ethics approval covers publication.” It does not. Committee review and the patient’s written consent to publication are separate requirements, and journals ask about them separately.
- “I can change the age and the dates to protect the patient.” ICMJE treats altering or falsifying details to achieve anonymity as unacceptable. Generalising and omitting are the permitted methods; inventing is not.
- “Masking the eyes in a photograph is enough.” ICMJE says explicitly that it is not adequate protection on its own.
Why one patient is the hardest case
A cohort study hides its participants in the aggregate. A case report does the opposite: it exists because this patient was unusual, and it earns its place in the literature by describing exactly how. Rosoff, in the Hastings Center Report, put the question bluntly — whether the case report can withstand ethical scrutiny at all — and the difficulty he identified is structural rather than fixable by better practice 11. The clinical specificity is the point of the article and the threat to the patient at the same time.
In a transplant report the specificity is unusually sharp. A unit keeps a small, well-documented list of recipients. Graft type, donor relationship, transplant date, maintenance regimen and the date of an acute illness are each weak identifiers alone and a strong one in combination, at least to anyone who works in that unit, knows the family, or has access to the registry. During the first waves of COVID-19 the problem was worse again, because for many centres there was exactly one such patient.
This matters for the language you use. Mostert and colleagues, in the European Journal of Human Genetics, describe how the familiar choice between obtaining consent and anonymising data collapses when the data are rich: the detail that survives anonymisation is often enough to re-identify 19. For a single-patient report, the honest description is that the data remain personal data, held in pseudonymised form, and that publication consent does the work that anonymisation cannot 17. Treat any claim that your case report is anonymous as a claim you would have to defend.
Three permissions, not one
Authors routinely collapse these into a single mental category called “consent”, and then discover at submission that the journal was asking about something else. Keep them separate on paper.
The first is a lawful basis for processing the patient’s health data for the purpose of writing and publishing this report. This is a data-protection question, answered by the organisation that holds the record — your hospital or university, acting as controller. Christofidou and colleagues, writing in Frontiers in Medicine, make the point that the GDPR offers six legal bases and consent is only one of them; which one applies to a case report is not a choice an individual author makes 6,21.
The second is your institution’s ethics position: whether a single de-identified case report counts as research requiring committee review. Practice differs, and this is one of the places where you should expect a different answer in a different country or even a different hospital. Many institutions treat an individual case report as clinical reporting rather than research and require no committee application; others require at least a waiver letter; some journals ask for documentation either way. Find out before you write, because retrofitting approval is usually impossible.
The third is the patient’s written informed consent to publication. This is a journal requirement and an ethical one, and it is independent of the other two. A lawful basis for processing does not supply publication consent, and publication consent does not supply a lawful basis 7. If you take one thing from this page, take that sentence.
The three permissions a single case report needs
| Permission | What it covers | Who decides | What appears in the manuscript |
|---|---|---|---|
| Lawful basis for processing data-protection law | Using the patient’s health record to write and publish the report at all | Your institution as data controller, advised by its data protection officer; the applicable national law varies | Usually nothing, but keep the written determination on file |
| Ethics committee position research governance | Whether a single case report is research requiring review, or is exempt | Your institutional review board or research ethics committee; practice differs by country and institution | A Methods statement naming the committee and reference number, or stating that review was not required and who determined that |
| Patient consent to publication journal and ethical requirement | Publishing this identifiable clinical narrative and these images, permanently and openly | The patient, in writing, on the journal’s form where one exists | An explicit statement that written informed consent for publication was obtained |
Requirements as stated in the ICMJE Recommendations and COPE Core Practices, with the data-protection row described from the GDPR as interpreted in European Commission and EDPB guidance. National implementations differ; confirm the first two rows with your own institution rather than relying on this summary.
What the GDPR requires, and what it leaves to your institution
The GDPR contains no provision about case reports. It regulates the processing of personal data, treats data concerning health as a special category needing an additional condition before it can be processed at all, and sets out six legal bases of which consent is one 21. That is the whole of what it says directly to you; everything more specific comes from national implementing law, regulator guidance, and your institution’s own determinations.
Where European guidance has spoken, it has tended away from consent as the research legal basis. The European Commission’s questions and answers on the interplay between the Clinical Trials Regulation and the GDPR concluded that consent will not be the appropriate legal basis in most cases, and the European Data Protection Board addressed the same interplay in its Opinion 3/2019 13,15. Vlahou and colleagues, in Hypertension, and Chassang, in ecancermedicalscience, both describe the resulting friction between what research ethics asks for and what data-protection law asks for; Gefenas and colleagues, in Medicine, Health Care and Philosophy, describe informed consent as sitting at a cross-road between the two regimes 7,9,18. None of this is settled doctrine about case reports specifically, and nobody should pretend otherwise.
Two practical consequences follow. First, the national layer is real: the Regulation expressly allows Member States to legislate further conditions for health and research data, so what is permitted for a retrospective look at a patient’s record differs between countries. Crowhurst and colleagues, in Nurse Researcher, work through this for retrospective reviews of patients’ data and reach a cautious conclusion 12. Second, outside the EU and EEA — the UK since its own post-Brexit regime, and institutions elsewhere entirely — different law applies, while the journal’s consent requirement does not change at all.
Pubrica’s position on this is deliberately narrow. We describe what the requirement is and where it varies. We do not give legal advice, and the right next step for any specific case is a short written question to your institution’s data protection officer or ethics committee, kept on file with the manuscript.
Source: Christofidou M, Arvanitis TN, Kalra D, Lea N, Shabani M, Coorevits P. Data altruism and the ‘consent’ question. Frontiers in Medicine.
What journals require, which is the part you control
The data-protection question depends on your jurisdiction. The publication requirements do not, and they are specific enough to work from today. The ICMJE Recommendations state that patients have a right to privacy that should not be violated without informed consent; that identifying details should be omitted if they are not essential; that where identifying information is essential, written informed consent must be obtained and a statement to that effect must appear in the published article; and that because complete anonymity is hard to achieve, consent should be sought whenever there is any doubt 1. They also say that masking the eye region in a photograph is inadequate protection, and that altering or falsifying details in order to achieve anonymity is not acceptable 1.
The ICMJE further requires that research conform to the Declaration of Helsinki, most recently revised in October 2024, and that approval by an independent ethics committee or institutional review board be stated in the Methods 1,26. Where no approval was required for a single case report, say that, and say who determined it.
Beyond the ICMJE baseline, individual journals operate their own consent forms, and for case reports these are often mandatory rather than optional — a signed form on the journal’s own template, uploaded at submission, with the original retained by you and not by the journal. Our notes on patient-identifiable consent and on journal consent forms for case reports cover the practical differences. COPE’s Core Practices give editors the framework they will use if a consent dispute arises after publication, which is a good reason to get the paperwork right before it 5.
One uncomfortable implication: if the patient cannot be traced, or has died and no one can consent on their behalf, the ICMJE position leads to not publishing rather than to publishing a more heavily disguised version. That is a real constraint on COVID-era transplant reporting and it is better confronted at the outset than at revision.
What to remove from a transplant case description
De-identification in a single-patient report is a judgement about combinations, not a list of fields to delete. The working test is: could a colleague in this unit, a family member, or someone with access to the national registry read this paragraph and know who it is? Run through the following, in this order.
- Direct identifiers. Name, initials, hospital or record number, national identifier, the names of relatives. Also the file names and metadata of any image you upload.
- Dates. Replace calendar dates with intervals. “Transplanted 14 March 2019, presented 2 April 2020” becomes “presented 13 months after transplantation” 6. The interval is the clinically meaningful quantity; the calendar date is only an identifier.
- Place. City, named institution in the case narrative, and travel destinations. If travel matters, describe it epidemiologically — travel to an area with sustained community transmission — rather than geographically.
- Uniqueness claims. “The only recipient in our unit infected during the first wave” is an identifier wearing a clinical costume. So is “our first paediatric case”.
- Third parties. A living related donor is a second person whose data you are also publishing and who has not consented. “Live-related transplantation” may be necessary; “his elder sister” rarely is.
- Exact age and occupation. Use a band. An exact age plus an unusual occupation plus a transplant history is frequently unique.
- Images. Faces, tattoos, jewellery, ward backgrounds, radiographs carrying burned-in demographics. Crop or recapture rather than redact.
What to keep is everything that carries the clinical message: the indication for transplantation, the maintenance immunosuppression and its doses or target levels, baseline and peak renal function, the confirmatory test, the changes you made to immunosuppression, the supportive care, and the outcome including graft function at follow-up. Reports lose far more value from under-reporting treatment than from over-generalising demography 16,27.
The same case, written two ways
The difference between an identifiable case description and a publishable one is not a matter of tone or of vagueness. It is a matter of which facts are doing which job. Compare the two paragraphs below: the second is longer, reports the management more completely, and identifies nobody.
An identifiable case description, and a publishable one
Identifies the patient
A 34-year-old bank accountant from Colombo underwent live-related renal transplantation at our institute on 14 March 2019, his elder sister being the donor. He attended our outpatient clinic on 2 April 2020 with three days of fever and dry cough, nine days after returning from a family wedding in Lombardy. He is the only transplant recipient in our unit to have been infected during the first wave. Figure 2 is a photograph taken at the bedside.
Exact age, occupation and city together. Within a single transplant unit’s catchment this combination is frequently unique.
Two calendar dates. The transplant date and the clinic date locate the case precisely in the unit’s own records.
A uniqueness claim. “The only recipient in our unit infected during the first wave” is an identifier presented as a clinical observation.
A second, non-consenting person. The donor’s relationship identifies a living family member whose data is also being published.
A bedside photograph and a named destination. Neither carries clinical information; both carry identifying information.
No treatment detail at all. The paragraph says what happened to the patient and nothing about what the team did.
Reports the medicine, not the person
A man in his thirties presented 13 months after live-related kidney transplantation with three days of fever and dry cough, following travel to an area with sustained community transmission. Maintenance immunosuppression was tacrolimus, mycophenolate mofetil and low-dose prednisolone, and serum creatinine had been stable over the preceding six months. SARS-CoV-2 infection was confirmed by RT-PCR on a nasopharyngeal swab. Mycophenolate was withheld, tacrolimus was continued at a reduced target trough concentration, and the prednisolone dose was unchanged. He was managed entirely as an outpatient with daily telephone review and recovered without hypoxaemia, graft dysfunction or admission; creatinine had returned to baseline at eight weeks.
Age as a band and time as an interval from transplantation keep the clinically relevant chronology without fixing a date.
Travel is described by its epidemiological relevance rather than its location.
The regimen, the specific change to immunosuppression and the outcome — the actual contribution — are all present and more fully reported than in the first version.
No third party is identifiable.
Nothing has been altered or invented. Detail has only been removed or generalised.
The second version is not vaguer about the medicine; it is vaguer about the person and far more precise about the care. Every clinically load-bearing element survives, while the elements that identified the patient, the donor and the centre are gone. Note what was not done: no date was shifted and no characteristic was swapped for a plausible alternative. ICMJE treats falsifying details to achieve anonymity as unacceptable, so generalisation and omission are the only available tools — and, as the CARE development work shows, the detail most often missing from case reports is the treatment, not the demography.
Fitting it to CARE without losing the clinical message
Once the consent and de-identification work is done, the reporting structure is the easy part. The CARE guidelines, developed by Gagnier and colleagues and published in BMJ Case Reports and the Journal of Medical Case Reports, give a 13-item checklist produced by a consensus process involving 27 participants of 28 contacted, with 18 of the phase I participants attending the face-to-face meeting 6. Riley and colleagues’ explanation and elaboration document in the Journal of Clinical Epidemiology works through each item with examples.
The item worth dwelling on is the therapeutic intervention. The CARE development work cites a review of 1,316 case reports across four journals in which more than half lacked primary treatment information — which is to say that the single most useful thing a case report can contain was missing from the majority of them. For a transplant patient with COVID-19 the treatment detail is the entire contribution: which agent was withheld, for how long, what the tacrolimus target was changed to, whether steroids were altered, and what happened to the graft. Strip demography hard and report therapy in full; most authors do the reverse.
Our guide to writing a case report covers the structure item by item, and the reporting guidelines hub places CARE alongside CONSORT, STROBE and PRISMA for the other study types. Vandenbroucke’s defence of case reports and case series in Annals of Internal Medicine remains the best short statement of what this study design is actually for, which is worth reading before you decide what your report is claiming 29.
Figures from the CARE development work. Source: Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Reports.
What the consent conversation has to cover
A signature on a form is evidence of a conversation, not a substitute for one 2. For a case report the conversation is short and it has specific content. Tell the patient what will be published and in what detail; that it will appear in a journal that may be freely accessible on the internet and indexed permanently; that it may be read by colleagues who could recognise the case; that any images will be included and which ones; that the report cannot reliably be withdrawn once published, although a journal can retract; and that declining has no effect whatsoever on their care. Then record, in the notes, that this conversation happened and when.
Two refinements are worth the extra minute. First, consent to publication of a case report should be specific rather than open-ended — the patient is agreeing to this article, not to future use of their record. The broader debate about open-ended permissions is live: Christofidou and colleagues, in Frontiers in Medicine, screened 6,780 records, removed 415 duplicates and included 60 publications, from which they identified 13 distinct consent models, and found dynamic consent favoured in 15 references against 6 for meta-consent, while broad consent remained contested 6. Kaye and colleagues set out the dynamic-consent proposal in the European Journal of Human Genetics and Ploug and Holm set out meta-consent in the BMJ 22,24. None of this is yet standard practice for case reports, and a specific one-off consent remains the safe position.
Second, if the patient lacks capacity, or is a child, or has died, the route is different in every jurisdiction and you need the institutional answer in writing rather than a reading of the Regulation. Where consent genuinely cannot be obtained, the ICMJE line leads to not publishing. Our page on the informed consent form covers the document itself.
Where this is genuinely unsettled
Three things are not resolved and you should not write as though they were.
Whether a single case report is “research” for the purposes of ethics review has no common European answer. Institutions differ, national rules differ, and journals ask the question in different ways. The practical response is to get your own institution’s answer in writing and quote it in the Methods.
What patients themselves want does not line up neatly with regulator caution. Christofidou and colleagues cite a study in which up to 98% of participants favoured broad consent for secondary use of their data, and Richter and colleagues, in the European Journal of Human Genetics, asked whether research use of clinical data without consent is not only legal but also acceptable to patients, and found more acceptance than the regulatory debate implies 6,14. That tension is unresolved. It is not a licence to skip consent for a case report; it is a reason to expect the rules to keep moving.
And the disagreement among commentators is substantive rather than cosmetic. Rumbold and Pierscionek, in the Journal of Medical Internet Research, and the European Society for Medical Oncology position paper by Casali in Annals of Oncology, reached notably different judgements about how much the Regulation would obstruct medical research 17,25. The honest summary is that the law is clear in outline and contested in application, that national implementations differ, and that the only reliable route for a specific manuscript is a written answer from your own data protection officer or ethics committee.
Take-home message
Take-home message
A single-patient transplant report is rarely anonymous, so stop describing it that way and secure the patient’s written consent to publication instead. Keep three permissions separate: a lawful basis for processing, which your institution determines; an ethics committee position, which differs by country and institution; and the patient’s consent to publication, which the journal will check. De-identify by converting dates to intervals, ages to bands and places to epidemiological descriptions, and by deleting uniqueness claims and third-party relationships — never by altering facts. Then report the therapy in full, because that is what most case reports are missing. For the data-protection questions, get a written answer from your own data protection officer; nothing on this page is a substitute for it.
How to apply this to your study
How to apply this to your own study
- Ask the consent question before you write a word. Send one short email to your data protection officer and one to your ethics committee office, asking what basis applies and whether review is required. Keep both replies with the manuscript file.
- Get the patient’s written consent on the target journal’s own form. If you have not chosen a journal yet, choose one now, because some forms are mandatory and non-interchangeable.
- Convert every calendar date in your draft to an interval. Months since transplantation, days since symptom onset. Then search the draft for any remaining year.
- Delete every uniqueness claim. “Our first”, “the only”, “the youngest”. These add nothing and identify directly.
- Check each third party. If a donor, relative or colleague is identifiable from your text, generalise the relationship or remove it.
- Audit your images and their metadata. Crop out faces, ward furniture and burned-in demographics, and re-export files so the original filenames and EXIF data do not travel with them.
- Run the draft against the 13 CARE items, paying particular attention to the therapeutic intervention item — dose, duration, and what was changed and when.
- Write the ethics and consent statements explicitly, naming the committee and reference number or stating why review was not required, plus a sentence confirming written consent for publication.
Common questions
Those are two different permissions and the answer differs for each. For publication you need the patient’s written informed consent, which the ICMJE requires and most journals enforce with their own form. For processing the patient’s health data in the first place, you need a lawful basis under data-protection law, and consent is only one of the six bases the GDPR provides. European guidance, including the European Commission’s questions and answers on the Clinical Trials Regulation and the EDPB’s Opinion 3/2019, has generally concluded that consent is not the appropriate legal basis for health research. Your institution decides which basis applies; your data protection officer should confirm it in writing.
Rarely, and you should not claim it. Mostert and colleagues, in the European Journal of Human Genetics, describe how the consent-or-anonymise approach breaks down on rich clinical data, and a transplant case is as rich as it gets: graft type, donor relationship, regimen, transplant timing and the date of an acute illness together identify one person to anyone inside that unit. The workable position is that the data remain personal data in pseudonymised form, that you minimise identifiers aggressively, and that the patient’s written consent to publication is what makes publication acceptable rather than a claim of anonymity.
Direct identifiers first: name, record number, relatives’ names, image metadata. Then dates, replaced by intervals from transplantation or symptom onset. Then places, including the named institution in the narrative and any travel destination, which should be described epidemiologically instead. Then uniqueness claims such as “the only recipient in our unit infected during the first wave”. Then third parties, especially a living related donor. Then exact age and unusual occupation, which should become a band and a generalisation. Keep the indication for transplantation, the full immunosuppressive regimen, renal function, the confirmatory test, every change you made to treatment, and the outcome.
This is the hardest version of the problem and the honest answer is unwelcome. The ICMJE position is that where identifying information is essential and consent cannot be obtained, the report should not be published — and heavier disguising is not an alternative, because altering details to achieve anonymity is itself unacceptable. For a deceased patient, whether a relative or legal representative can consent is governed by national law and institutional policy rather than by the GDPR alone, so this is precisely a question for your ethics committee rather than for a general guide. Ask before you invest the writing time.
There is no single European answer and you should expect practice to differ. Many institutions treat an individual case report as clinical reporting rather than research and require no application; others require a formal exemption or waiver letter; some journals ask for documentation whichever way the institution has decided. The ICMJE requires that approval by an independent ethics committee or institutional review board be stated in the Methods where research is involved, and that research conform to the Declaration of Helsinki, most recently revised in October 2024. Get your institution’s determination in writing and quote it in the Methods, including the case where review was not required.
No. The ICMJE is explicit that altering or falsifying details in order to achieve anonymity is not acceptable, because a reader cannot then tell which parts of the clinical narrative are real. The permitted operations are omission and generalisation: a man in his thirties rather than a 34-year-old, thirteen months after transplantation rather than a calendar date, an area with sustained community transmission rather than a named region. These lose nothing a reader needs and they do not corrupt the record. Shifting dates by a few weeks, by contrast, quietly damages a chronology that other clinicians may be trying to learn from.
Tell the patient what will appear and in what detail, that it will be published in a journal that may be openly accessible and permanently indexed, that colleagues who know the case might recognise it, which images will be included, that publication cannot reliably be undone although a journal can retract, and that declining will not affect their care in any way. Record the conversation in the notes with its date, and keep the signed form yourself. Keep the consent specific to this article; open-ended permissions for future use are a separate and contested question, where Christofidou and colleagues found 13 different consent models in use and no settled standard.
No, and we are deliberate about that. This page describes what the ICMJE, COPE, CARE and journal consent policies require of authors, which is the part a researcher can act on today, and it describes the shape of the data-protection requirement and where national implementations diverge. It does not tell you which legal basis applies to your processing, because that depends on your jurisdiction, your institution’s role as controller and the national implementing law. For that, send a written question to your data protection officer or ethics committee and keep the answer with the manuscript.
References and sources
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- Tam NT, Huy NT, Thoa TB, Long NP, Trang NT, Hirayama K, et al. Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bulletin of the World Health Organization. 2015;93:186-198H. doi:10.2471/BLT.14.141390 read 9 October 2026. doi.org/10.2471/BLT.14.141390
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- World Health Organization. Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants. WHO. 2011. read 9 October 2026. equator-network.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- Christofidou M, Arvanitis TN, Kalra D, Lea N, Shabani M, Coorevits P. Data altruism and the 'consent' question: a study into the 'consent' models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data. Frontiers in Medicine. 2025;11:1489925. doi:10.3389/fmed.2024.1489925 read 9 October 2026. doi.org/10.3389/fmed.2024.1489925
- Gefenas E, Lekstutiene J, Lukaseviciene V, Hartlev M, Mourby M, Cathaoir KO. Controversies between regulations of research ethics and protection of personal data: informed consent at a cross-road. Medicine, Health Care and Philosophy. 2022;25:23-30. doi:10.1007/s11019-021-10060-1 read 9 October 2026. doi.org/10.1007/s11019-021-10060-1
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, et al. Data sharing under the General Data Protection Regulation: time to harmonize law and research ethics? Hypertension. 2021;77:1029-1035. doi:10.1161/HYPERTENSIONAHA.120.16340 read 9 October 2026. doi.org/10.1161/HYPERTENSIONAHA.120.16340
- European Data Protection Board. Document on response to the request from the European Commission for clarifications on the consistent application of the GDPR, focusing on health research. EDPB. 2021. read 9 October 2026. ejprarediseases.org
- Rosoff PM. Can the case report withstand ethical scrutiny? The Hastings Center Report. 2019;49(6):17-21. read 9 October 2026. community.the-hospitalist.org
- Crowhurst N, Bergin M, Wells J. Implications for nursing and healthcare research of the General Data Protection Regulation and retrospective reviews of patients' data. Nurse Researcher. 2019;27(1):45-49. doi:10.7748/nr.2019.e1639 read 9 October 2026. doi.org/10.7748/nr.2019.e1639
- European Data Protection Board. Opinion 3/2019 concerning the Questions and Answers on the interplay between the Clinical Trials Regulation and the GDPR. EDPB. 2019. read 9 October 2026. lw.com
- Richter G, Borzikowsky C, Lieb W, Schreiber S, Krawczak M, Buyx A. Patient views on research use of clinical data without consent: legal, but also acceptable? European Journal of Human Genetics. 2019;27:841-847. doi:10.1038/s41431-019-0340-6 read 9 October 2026. doi.org/10.1038/s41431-019-0340-6
- European Commission, Directorate-General for Health and Food Safety. Questions and Answers on the interplay between the Clinical Trials Regulation and the General Data Protection Regulation. European Commission. 2019. read 9 October 2026. research.uci.edu
- Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology. 2017;89:218-235. read 9 October 2026. community.the-hospitalist.org
- Rumbold JMM, Pierscionek BK. The effect of the General Data Protection Regulation on medical research. Journal of Medical Internet Research. 2017;19(2):e47. doi:10.2196/jmir.7108 read 9 October 2026. doi.org/10.2196/jmir.7108
- Chassang G. The impact of the EU general data protection regulation on scientific research. ecancermedicalscience. 2017;11:709. doi:10.3332/ecancer.2017.709 read 9 October 2026. doi.org/10.3332/ecancer.2017.709
- Mostert M, Bredenoord AL, Biesaart MC, van Delden JJ. Big data in medical research and EU data protection law: challenges to the consent or anonymise approach. European Journal of Human Genetics. 2016;24:956-960. doi:10.1038/ejhg.2015.239 read 9 October 2026. doi.org/10.1038/ejhg.2015.239
- Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-related Research Involving Humans, 4th edition. CIOMS. 2016. read 9 October 2026. equator-network.org
- European Union. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation). Official Journal of the European Union. 2016. read 9 October 2026. frontiersin.org
- Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic consent: a patient interface for twenty-first century research networks. European Journal of Human Genetics. 2015;23:141-146. doi:10.1038/ejhg.2014.71 read 9 October 2026. doi.org/10.1038/ejhg.2014.71
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Ploug T, Holm S. Meta consent: a flexible and autonomous way of obtaining informed consent for secondary research. BMJ. 2015;350:h2146. doi:10.1136/bmj.h2146 read 9 October 2026. doi.org/10.1136/bmj.h2146
- Casali PG; European Society for Medical Oncology. Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community. Annals of Oncology. 2014;25:1458-1461. doi:10.1093/annonc/mdu218 read 9 October 2026. doi.org/10.1093/annonc/mdu218
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053 read 9 October 2026. doi.org/10.1001/jama.2013.281053
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223 read 9 October 2026. doi.org/10.1186/1752-1947-7-223
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Vandenbroucke JP. In defense of case reports and case series. Annals of Internal Medicine. 2001;134(4):330-334. read 9 October 2026. community.the-hospitalist.org
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. US Department of Health, Education, and Welfare. 1978. read 9 October 2026. frontiersin.org
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection. Pubrica. https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/
Pubrica Academy. “Writing up a Kidney Transplant Patient with Mild COVID-19: Consent, De-Identification and Data Protection.” Pubrica, 9 Oct. 2026, pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/.
Pubrica Academy (2026) Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection. Pubrica. Available at: https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/ (Accessed: 15 October 2026).
Pubrica Academy. “Writing up a Kidney Transplant Patient with Mild COVID-19: Consent, De-Identification and Data Protection.” Pubrica. October 9, 2026. https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/
Pubrica Academy, ‘Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/> accessed 15 October 2026.
Pubrica Academy. Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/
Pubrica Academy, “Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/
@misc{a_kidney_transplant_patient_with_mild__2026,
author = {{Pubrica Academy}},
title = {Writing up a kidney transplant patient with mild COVID-19: consent, de-identification and data protection},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/artical/a-kidney-transplant-patient-with-mild-covid‐19-case-report-writing-guidelines-for-publication-and-the-importance-of-gdpr/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Consent and de-identification checklist for a case report
Work through this before you draft, not at submission. The first block is the paperwork that cannot be retrofitted; the second is a line-by-line pass over the manuscript text. Paste it into your notes and answer every line in writing.
CASE REPORT: CONSENT AND DE-IDENTIFICATION CHECKLIST
Case: ______________________ Target journal: ______________________
A. PERMISSIONS (secure these before writing)
[ ] Written question sent to the institutional data protection officer
Date sent: __________ Reply received and filed: __________
Lawful basis stated by the institution: ______________________
[ ] Ethics committee position obtained in writing
Review required? YES -> ref no. __________ NO -> determined by __________
[ ] Patient's written informed consent to publication obtained
Journal's own form used? YES / NO (if the journal has one, it is usually mandatory)
Signed original retained by: ______________________
[ ] Consent conversation recorded in the clinical notes, with date
[ ] Where the patient lacks capacity, is a minor, or has died:
institutional route confirmed in writing: ______________________
B. CONSENT CONVERSATION (tick each point actually covered)
[ ] What will be published, and in what level of detail
[ ] That the journal may be openly accessible and permanently indexed
[ ] That colleagues involved in their care might recognise the case
[ ] Which images will be included, shown to the patient
[ ] That publication cannot reliably be withdrawn once it has happened
[ ] That declining has no effect on their care
C. TEXT PASS (search the draft for each of these)
[ ] No name, initials, record number or national identifier anywhere
[ ] No relative, donor or colleague identifiable
[ ] Every calendar date replaced by an interval (search the draft for "20")
[ ] No named city or institution in the case narrative
[ ] Travel described epidemiologically, not geographically
[ ] No uniqueness claims ("the only", "our first", "the youngest")
[ ] Exact age replaced by a band; unusual occupation generalised or cut
[ ] Nothing altered or invented to disguise the patient -- omission and
generalisation only
D. IMAGES
[ ] Faces, tattoos, jewellery and ward backgrounds cropped out
[ ] Burned-in demographics removed from radiographs
[ ] Files re-exported so original filenames and EXIF data do not travel
[ ] Patient has seen the specific images being submitted
E. CLINICAL COMPLETENESS (CARE, 13 items)
[ ] Indication for transplantation and time since transplant stated
[ ] Full maintenance immunosuppression with doses or target levels
[ ] Baseline and peak renal function
[ ] Diagnostic confirmation and method
[ ] EVERY change to therapy, with timing and duration -- the item most
often missing from published case reports
[ ] Outcome, including graft function at a stated follow-up point
[ ] Patient perspective, where obtainable
F. STATEMENTS IN THE MANUSCRIPT
[ ] Ethics: committee name and reference number, or why review was not required
[ ] Consent: explicit sentence that written informed consent for publication
was obtained from the patient
[ ] Declaration of Helsinki (October 2024 revision) conformity, where applicable Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.
How Pubrica helps
Pubrica’s medical writing team reads case reports the way a case-report editor does: consent paperwork first, then de-identification, then whether the therapy is actually reported. We will rewrite an identifiable case description into one that keeps the clinical message, flag the third parties and uniqueness claims most authors miss, and tell you which of the three permissions is missing from your file. We do not give legal opinions on data protection; we tell you precisely what to ask your data protection officer and ethics committee, and we draft the ethics and consent statements once you have their answers.